Advertisement
Canada markets close in 4 hours 44 minutes

  • S&P/TSX

    22,003.95
    +131.99 (+0.60%)
     

  • S&P 500

    5,063.97
    +53.37 (+1.07%)
     

  • DOW

    38,481.07
    +241.09 (+0.63%)
     

  • CAD/USD

    0.7316
    +0.0015 (+0.21%)
     

  • CRUDE OIL

    82.32
    +0.42 (+0.51%)
     

  • Bitcoin CAD

    91,274.43
    +1,270.17 (+1.41%)
     

  • CMC Crypto 200

    1,440.36
    +25.60 (+1.81%)
     

  • GOLD FUTURES

    2,329.60
    -16.80 (-0.72%)
     

  • RUSSELL 2000

    2,001.23
    +33.76 (+1.72%)
     

  • 10-Yr Bond

    4.5860
    -0.0370 (-0.80%)
     

  • NASDAQ

    15,669.38
    +218.08 (+1.41%)
     

  • VOLATILITY

    16.30
    -0.64 (-3.78%)
     

  • FTSE

    8,043.12
    +19.25 (+0.24%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6838
    -0.0012 (-0.18%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

Bio-Path Holdings, Inc.
·1 min read

HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 14, 2021 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2021 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5064037. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies. For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369